<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00539240</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-022-04F</org_study_id>
    <nct_id>NCT00539240</nct_id>
  </id_info>
  <brief_title>Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI</brief_title>
  <official_title>Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to compare the efficacy (how successful) 1) standard-dose
      proton pump inhibitor (PPI) (rabeprazole 20 mg once daily) (a medication that completely
      blocks the stomach from producing acid) plus low dose tricyclic antidepressant (nortriptyline
      50mg) (TCA); 2) double-dose PPI (rabeprazole 20 mg twice a day); to 3) standard-dose PPI
      (rabeprazole 20mg once daily) and placebo (an inactive substance, like a sugar pill) to
      determine the relative symptom resolution and health-related quality of life in
      gastroesophageal reflux disease (a disease characterized by a burning sensation (heartburn)
      behind the breast bone caused by a backflow of stomach contents into the esophagus) (GERD)
      patients who fail standard-dose PPI and you will be randomly assigned (similar to flipping a
      coin) to one of the three groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Failure of standard dose PPI to control GERD symptoms has been increasingly encountered in
      clinical practice (both primary care and sub-specialties) and has become one of the most
      challenging therapeutic dilemmas in GERD management. It has been estimated that up to 30% of
      the patients receiving PPI once daily will continue to report typical GERD symptoms [1].
      Presently, increasing the PPI dose has been the standard of care in these patients [2].
      However, success in relieving refractory GERD symptoms with such a therapeutic approach has
      been extremely limited, resulting in frustration of both the patient as well as the health
      care provided. Furthermore, patients who fail PPI will continue to seek medical attention and
      may undergo a variety of invasive or non-invasive tests, and thus consume already limited
      health care resources. Recent advancement in the understanding of the diverse composition of
      the different GERD groups as well as symptom generation has led to the recognition of
      alteration in pain perception as an important contributing factor for PPI failure in some and
      the presence of non-acid related stimuli in others [3].

      This study will clarify for the first time the role of pain modulation in patients who failed
      standard dose of PPI. The clinical experience with doubling the PPI dose, which is the
      current standard of care, has been very limited and relatively disappointing. Additionally,
      this study may identify the group of PPI failure patients that may benefit from doubling the
      dose of PPI and the group that will benefit more from adding a pain modulator. This study is
      timely, has never been performed and addresses a prevalent emerging clinical dilemma in GI as
      well as primary care clinics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Daytime Heartburn, Number of Days in Week Symptoms Intensity Score &lt; 3 (Better)</measure>
    <time_frame>Symptom control after 6 weeks of treatment</time_frame>
    <description>the number of days with Symptom Intensity Score &lt; 3 (better) for daytime heartburn during week 6 as compared to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nighttime Heartburn, Number of Days in Week Symptom Activity Score &lt;3 (Better) in Week 6 Compared to Baseline</measure>
    <time_frame>Symptom control after 6 weeks of treatment</time_frame>
    <description>the number of days with Symptom Intensity Score &lt; 3 (better) for nighttime heartburn during week 6 as compared to baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acid Regurgitation, Number of Days in Week Symptoms Intensity Score &lt; 3 (Better)</measure>
    <time_frame>Symptom control after 6 weeks of treatment</time_frame>
    <description>the number of days with Symptom Intensity Score &lt; 3 (better) for acid regurgitation during week 6 as compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life</measure>
    <time_frame>end of study</time_frame>
    <description>SF-36 Physical Component Score (higher number better quality of life), is a measure of overall physical quality of life distinct from mental health. The range is 0 - 100. It has been adjusted to US national norms so that a score of 50 corresponds to the national mean.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">236</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>Rabeprazole morning/evening placebo bedtime</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>AciPhex 20 mg BID and once daily placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rabeprazole breakfast, placebo dinner and bedtime</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>AcipHex 20 mg once daily and BID placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rabeprazole breakfast, placebo dinner, nortriptyline bedtime</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole 20mg, placebo dinner and bedtime</intervention_name>
    <description>Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime</description>
    <arm_group_label>Rabeprazole breakfast, placebo dinner and bedtime</arm_group_label>
    <other_name>AcipHex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole 20 mg two times, Placebo at bedtime</intervention_name>
    <description>Breakfast &amp; Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime</description>
    <arm_group_label>Rabeprazole morning/evening placebo bedtime</arm_group_label>
    <other_name>Aciphex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant</intervention_name>
    <description>Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime</description>
    <arm_group_label>Rabeprazole breakfast, placebo dinner, nortriptyline bedtime</arm_group_label>
    <other_name>Nortriptyline and Aciphex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Currently being treated with a PPI, but continue to experience GERD symptoms (such as
             heartburn) at least 2 times per week.

        Exclusion Criteria:

          -  Known allergy or intolerance to TCA

          -  History of serious arrhythmia or use of anti-arrhythmics

          -  History of seizures

          -  Subjects with significant co-morbidity, e.g., cardiovascular, respiratory, urogenital,
             renal, gastrointestinal, hepatic, hematological, endocrine, neurologic or psychiatric

          -  With evidence or history of drug abuse within the past 6 months

          -  Erosive esophagitis, esophageal ulceration, peptic stricture, Barrett's esophagus or
             adenocarcinoma of the esophagus on endoscopy

          -  History of esophagogastric surgery

          -  Gastric or duodenal lesions (ulcer, tumor, etc.)

          -  Women who are pregnant or of childbearing age who are not on contraception

          -  Patients who are unwilling or unable to provide informed consent

          -  Insulin dependent diabetes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Southern Arizona VA Health Care System, Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2007</study_first_submitted>
  <study_first_submitted_qc>October 3, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2007</study_first_posted>
  <results_first_submitted>February 7, 2014</results_first_submitted>
  <results_first_submitted_qc>July 29, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 18, 2014</results_first_posted>
  <last_update_submitted>July 29, 2014</last_update_submitted>
  <last_update_submitted_qc>July 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acid reflux</keyword>
  <keyword>acid regurgitation</keyword>
  <keyword>esophagitis</keyword>
  <keyword>GERD</keyword>
  <keyword>heartburn</keyword>
  <keyword>pain</keyword>
  <keyword>peptic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
    <mesh_term>Nortriptyline</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
    <mesh_term>Antidepressive Agents, Tricyclic</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment from GI clinic in VA medical center between 4/19/2006 and 3/31/2010</recruitment_details>
      <pre_assignment_details>Eligibility screening occurred prior to randomization. Of 236 patients enrolled, 68 patients were not randomized due to abnormal endoscopy (14 patients), asymptomatic during run-in period (2 patients), lost to follow-up (11 patients), consent withdrawal, protocol deviation and screen failure (32 patients) and other causes (9 patients).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1</title>
          <description>AciPhex 20 mg BID and once daily placebo
Rabeprazole 20mg, placebo dinner and bedtime: Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime</description>
        </group>
        <group group_id="P2">
          <title>Arm 2</title>
          <description>AcipHex 20 mg once daily and BID placebo
Rabeprazole 20 mg two times, Placebo at bedtime: Breakfast &amp; Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime</description>
        </group>
        <group group_id="P3">
          <title>Arm 3</title>
          <description>AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily
Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant: Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="55"/>
                <participants group_id="P3" count="54"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Number of randomized subjects</population>
      <group_list>
        <group group_id="B1">
          <title>AciPhex 20 mg BID and Once Daily Placebo</title>
          <description>AciPhex 20 mg BID and once daily placebo
Rabeprazole 20mg, placebo dinner and bedtime: Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime</description>
        </group>
        <group group_id="B2">
          <title>AcipHex 20 mg Once Daily and BID Placebo</title>
          <description>AcipHex 20 mg once daily and BID placebo
Rabeprazole 20 mg two times, Placebo at bedtime: Breakfast &amp; Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime</description>
        </group>
        <group group_id="B3">
          <title>AcipHex 20 mg Once, Placebo Once, Nortriptyline</title>
          <description>AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily
Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant: Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="54"/>
            <count group_id="B4" value="168"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="13.8"/>
                    <measurement group_id="B2" value="54.8" spread="13.4"/>
                    <measurement group_id="B3" value="56" spread="11.5"/>
                    <measurement group_id="B4" value="55.6" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="54"/>
                    <measurement group_id="B4" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/meter-squared</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.4" spread="6.1"/>
                    <measurement group_id="B2" value="29.3" spread="6.5"/>
                    <measurement group_id="B3" value="29.8" spread="4.6"/>
                    <measurement group_id="B4" value="29.5" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Daytime Heartburn, Number of Days in Week Symptoms Intensity Score &lt; 3 (Better)</title>
        <description>the number of days with Symptom Intensity Score &lt; 3 (better) for daytime heartburn during week 6 as compared to baseline</description>
        <time_frame>Symptom control after 6 weeks of treatment</time_frame>
        <population>intention to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>AciPhex 20 mg BID and once daily placebo
Rabeprazole 20mg, placebo dinner and bedtime: Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>AcipHex 20 mg once daily and BID placebo
Rabeprazole 20 mg two times, Placebo at bedtime: Breakfast &amp; Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily
Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant: Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Daytime Heartburn, Number of Days in Week Symptoms Intensity Score &lt; 3 (Better)</title>
          <description>the number of days with Symptom Intensity Score &lt; 3 (better) for daytime heartburn during week 6 as compared to baseline</description>
          <population>intention to treat (ITT)</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="0.9"/>
                    <measurement group_id="O2" value="5.9" spread="2.2"/>
                    <measurement group_id="O3" value="6.1" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <p_value_desc>P&lt;0.05 considered statistically significant. No adjustment for multiple comparisons</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>adjusted for age, sex, BMI and ethnicity</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.50</p_value>
            <p_value_desc>P&lt;0.05 considered statistically significant, No adjustment for multiple comparisons</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>adjusted for age, sex, BMI and ethnicity</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Related Quality of Life</title>
        <description>SF-36 Physical Component Score (higher number better quality of life), is a measure of overall physical quality of life distinct from mental health. The range is 0 - 100. It has been adjusted to US national norms so that a score of 50 corresponds to the national mean.</description>
        <time_frame>end of study</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>AciPhex 20 mg BID and once daily placebo
Rabeprazole 20mg, placebo dinner and bedtime: Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>AcipHex 20 mg once daily and BID placebo
Rabeprazole 20 mg two times, Placebo at bedtime: Breakfast &amp; Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily
Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant: Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Health Related Quality of Life</title>
          <description>SF-36 Physical Component Score (higher number better quality of life), is a measure of overall physical quality of life distinct from mental health. The range is 0 - 100. It has been adjusted to US national norms so that a score of 50 corresponds to the national mean.</description>
          <population>ITT</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0" spread="10.3"/>
                    <measurement group_id="O2" value="37.7" spread="11.0"/>
                    <measurement group_id="O3" value="37.7" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <p_value_desc>P&lt;0.05 considered statistically significant. No adjustment for multiple comparisons (no post-hoc contrasts performed)</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Adjusted for baseline score and personality traits (SCL-90)</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Nighttime Heartburn, Number of Days in Week Symptom Activity Score &lt;3 (Better) in Week 6 Compared to Baseline</title>
        <description>the number of days with Symptom Intensity Score &lt; 3 (better) for nighttime heartburn during week 6 as compared to baseline</description>
        <time_frame>Symptom control after 6 weeks of treatment</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>AciPhex 20 mg BID and once daily placebo
Rabeprazole 20mg, placebo dinner and bedtime: Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>AcipHex 20 mg once daily and BID placebo
Rabeprazole 20 mg two times, Placebo at bedtime: Breakfast &amp; Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily
Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant: Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Nighttime Heartburn, Number of Days in Week Symptom Activity Score &lt;3 (Better) in Week 6 Compared to Baseline</title>
          <description>the number of days with Symptom Intensity Score &lt; 3 (better) for nighttime heartburn during week 6 as compared to baseline</description>
          <population>ITT</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="0.9"/>
                    <measurement group_id="O2" value="5.8" spread="2.0"/>
                    <measurement group_id="O3" value="6.0" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <p_value_desc>P&lt;0.05 considered statistically significant, No adjustment for multiple comparisons</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>adjusted for age, sex, BMI and ethnicity.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.50</p_value>
            <p_value_desc>P&lt;0.05 considered statistically significant, no adjustment for multiple comparisons</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>adjusted for age, sex, BMI and ethnicity</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Acid Regurgitation, Number of Days in Week Symptoms Intensity Score &lt; 3 (Better)</title>
        <description>the number of days with Symptom Intensity Score &lt; 3 (better) for acid regurgitation during week 6 as compared to baseline</description>
        <time_frame>Symptom control after 6 weeks of treatment</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1</title>
            <description>AciPhex 20 mg BID and once daily placebo
Rabeprazole 20mg, placebo dinner and bedtime: Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime</description>
          </group>
          <group group_id="O2">
            <title>Arm 2</title>
            <description>AcipHex 20 mg once daily and BID placebo
Rabeprazole 20 mg two times, Placebo at bedtime: Breakfast &amp; Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime</description>
          </group>
          <group group_id="O3">
            <title>Arm 3</title>
            <description>AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily
Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant: Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime</description>
          </group>
        </group_list>
        <measure>
          <title>Acid Regurgitation, Number of Days in Week Symptoms Intensity Score &lt; 3 (Better)</title>
          <description>the number of days with Symptom Intensity Score &lt; 3 (better) for acid regurgitation during week 6 as compared to baseline</description>
          <population>ITT</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="48"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" spread="0.8"/>
                    <measurement group_id="O2" value="5.9" spread="2.1"/>
                    <measurement group_id="O3" value="6.3" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <p_value_desc>P&lt;0.05 considered statistically significant. No adjustment for multiple comparisons.</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>adjusted for age, sex, BMI and ethnicity</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.20</p_value>
            <p_value_desc>P&lt;0.05 considered statistically significant. No adjustment for multiple comparisons.</p_value_desc>
            <method>Regression, Linear</method>
            <method_desc>adjusted for age, sex, BMI and ethnicity.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm 1</title>
          <description>AciPhex 20 mg BID and once daily placebo
Rabeprazole 20mg, placebo dinner and bedtime: Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime</description>
        </group>
        <group group_id="E2">
          <title>Arm 2</title>
          <description>AcipHex 20 mg once daily and BID placebo
Rabeprazole 20 mg two times, Placebo at bedtime: Breakfast &amp; Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime</description>
        </group>
        <group group_id="E3">
          <title>Arm 3</title>
          <description>AcipHex 20 mg once daily, placebo once daily and nortriptyline once daily
Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant: Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>skin ulceration</sub_title>
                <description>ulcer on tongue</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <description>&quot;Stomach cramps&quot;</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 10.0">Flu like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <description>&quot;Drowsiness&quot;</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Other, Renal and urinary disorders</sub_title>
                <description>&quot;urinary difficulty&quot; (type unspecified)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Other, Skin and subcutaneous tissue disorders</sub_title>
                <description>Rash (type unspecified) on face</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Recruitment challenges, including difficulty finding patients who &quot;fail&quot; PPI but had not already been prescribed doubled dose. Necessitated a no-cost extension to complete recruitment</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Christopher Wendel, MS</name_or_title>
      <organization>Southern Arizona VA Health Care System</organization>
      <phone>520 792 1450 ext 1824</phone>
      <email>christopher.wendel@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

